



Myrexis to Hold Conference Call to Discuss Fiscal Second Quarter 2011 Financial Results

SALT LAKE CITY, Feb. 1, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will hold a conference call on Wednesday, Feb 9, 2011 at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results for its fiscal second quarter 2011 ended December 31, 2010.

The conference call will be hosted by Adrian Hobden, Ph.D., President and Chief Executive Officer and Robert Lollini, Chief Financial Officer and Treasurer.

To participate, please dial 877-312-5447 (USA) or 253-237-1129 (International); Conference ID: 41570338. To access the live web cast please visit the Investor Relations section on the corporate web site at www.myrexis.com.

A replay of the conference call will be available beginning February 9, 2011 at 7:30 p.m. ET (4:30 p.m. PT) and ending on March 9, 2011 by dialing 800-642-1687 (USA) or 706-645-9291 (International), Conference ID: 41570338. A replay of the webcast will also be available on the corporate website for one month, through March 9, 2011.

About Myrexis, Inc.

Myrexis, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a robust pipeline of clinical and pre-clinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in human genetics, protein-protein interaction technology, chemical proteomics, drug discovery and clinical and commercial development.

The Company's oncology pipeline is led by [Azixa](#) (verubulin, MPC-6827), a novel small molecule microtubule destabilizing agent in Phase 2 clinical development for the treatment of brain cancers. Additional novel, potent, small molecule oncology compounds include [MPC-3100](#), a fully-synthetic inhibitor of Hsp90 in Phase 1 clinical development; and [MPC-9528](#), a Cancer Metabolism Inhibitor (CMI) in IND-enabling studies. Myrexis is also evaluating [MPI-0485520](#), an orally bioavailable, potent and selective small molecule inhibitor of type I interferon production that is being developed for cancer and chronic inflammation.

For more information, please visit www.myrexis.com.

The Myrexis, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=6327>

Azixa, Myrexis and the Myrexis logo are trademarks or registered trademarks of Myrexis, Inc. in the United States and foreign countries.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes, expected development, and potential efficacy of Myrexis' product candidates, including Azixa (MPC-6827). These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to, the factors discussed under the heading "Risk Factors" contained in Myrexis' Form 10-K, for the year ended June 30, 2010, which was filed with the Securities and Exchange Commission on September 13, 2010, as well as any updates to those risk factors filed from time to time in Myrexis' Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis undertakes no duty to update this information unless required by law.

CONTACT: Myrexis, Inc.

Patrick M. Burke, Ph.D., V.P.

Corporate and Business Development

801-214-7822

investor.relations@myrexix.com

The Ruth Group

Sara Pellegrino (investors)

(646) 536-7002

spellegrino@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com